Publication

Article

Pharmacy Times

September 2013 Oncology
Volume79
Issue 9

Clinical Guidelines May Reduce Unnecessary Prostate Cancer Imaging

Providing clinicians with prostate cancer imaging information and guidelines may help to reduce the amount of inappropriate imaging, suggests a recent study conducted in Sweden.

To reduce national rates of inappropriate prostate cancer imaging, the national Prostate Cancer Register of Sweden has supplied urologists with imaging guidelines and utilization data since 2000. The study, published online on July 13, 2013, in the Journal of the National Cancer Institute, analyzed the effects of this campaign on prostate cancer imaging rates in 99,879 men diagnosed with prostate cancer from 1998 to 2009. Cancers were categorized as low, intermediate, or high risk, and imaging rates were evaluated over time and regionally.

A total of 36% of participants underwent imaging within 6 months of their prostate cancer diagnosis. Among men with low-risk prostate cancer, imaging rates decreased from 45% before the campaign to just 3% in 2009. Imaging rates for high-risk cancer patients decreased as well, from 63% to 47%. Although the results varied by region, each area experienced statistically significant drops in prostate cancer imaging.

Inappropriate use of imaging in low-risk prostate cancer patients is a problem recognized by organizations such as the American Society of Clinical Oncology. The authors suggest that a US campaign to promote imaging guidelines may also be effective in reducing prostate cancer imaging.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com